# Artivion Inc. (AORT) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Technology. Price $25.57, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Artivion Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.20**. A PEG of 0.20 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 30.9×**. Enterprise value is 30.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: -0.7%** (5-yr avg -0.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 64.4%**. Artivion Inc. keeps 64.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 4.4%**. 4.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 2.2%**. 2.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 2.2%**. 2.2% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 2.7%**. Return on all capital, debt included, is 2.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.4%**. Each dollar of assets produces -0.4% of profit.

## Growth
- **Revenue growth (1 yr): 13.6%** (3-yr 12.0%/yr, 5-yr 11.8%/yr). Revenue grew 13.6% over the last year, against 11.8% a year compounded over five years.
- **EPS growth (1 yr): 165.6%**. Earnings per share rose 165.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.48**. Debt is 0.48 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 3.3×**. It would take 3.3 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 3.05**. A Z-score of 3.05 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Artivion Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Artivion Inc.; the consensus is strong_buy, with an average price target of $42.15 (+65% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -41.9%** (YTD -43.9%, 3-mo 27.1%). The shares are down 41.9% over twelve months including dividends.
- **From 52-week high: -47.0%** (33.5% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.45** (volatility 48%). Beta of 0.45 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AORT · Page: https://foliofundamentals.com/stocks/aort

Not investment advice.